Faron Pharmaceuticals Provides Update of Bexmarilimab in P-I/II Study (BEXMAB) for the Treatment of Hematological Malignancies
Shots:
- The P-I/II study (BEXMAB) evaluating the safety, tolerability & preliminary efficacy of bexmarilimab + SoC (azacitidine & venetoclax)
- The results showed the objective response in 3 out of 5 patients in 1st doublet cohort, 2 out of 3 responders were refractory to prior azacitidine monotx., was well-tolerated with no DLTs or safety concerns in 5 patients who received 1mg/kg, qw dosing with azacitidine, no additional AEs were observed
- Bexmarilimab was dosed at 1mg/kg for the initial cohort while rapid enrollment is ongoing into doublet & triplet combinations. In 1st cohort, the patient achieved a CR with incomplete blood cell count recovery after 4 treatment cycles, followed by full blood count recovery after 5 treatment cycles & the results also showed PR
Ref: Cision | Image: Faron
Related News:- Faron Reports 12-Month Survival Results of Bexmarilimab in P-I/II (MATINS) Study for the Treatment of Solid Tumor
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
